Abacavir-Based ART Regimens Linked to Higher MACE Risk in Patients With HIV
|
The risk for MACEs was higher among patients with HIV
infection receiving abacavir- vs tenofovir-based ART regimens. |
FDA slaps clinical hold on multiple Gilead HIV trials
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns. View article...